Multi-Valor AIF Umbrella Fund SICAV Quintus Growth Fund disclosed a 9.99% beneficial ownership in Conexeu Sciences Inc. on September 4, 2026. The holding comprises 4,400,305 common shares. This total includes 2,200,000 common share warrants. The Schedule 13G filing clarifies the stake is for investment purposes and not intended to influence company control.
Conexeu is a preclinical-stage biotechnology firm developing the CXU regenerative tissue platform. The company has experienced high stock price volatility since its direct listing in May 2026. This institutional investment follows a September 1 announcement regarding Conexeu’s participation in three investor and industry conferences scheduled for September and October 2026.